Acasti Pharma and CordenPharma Announce Large-Scale Production of CaPre with Continuous Manufacturing

Acasti Pharma achieved the milestone of manufacturing the first cGMP batches of CaPre, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary continuous manufacturing process developed in partnership with CordenPharma, the companies announced in a press release on June 1, 2017. The process was jointly designed and implemented by the Acasti and CordenPharma technical teams and engineers at the CordenPharma Chenôve facility in Dijon, France.

This continuous manufacturing process allows an increased throughput and a small equipment footprint. The process is designed to purify the bioactive molecules of the raw krill oil through continuous and consecutive decantations. This approach will enable improved quality control and cGMP compliance, while reducing energy consumption, waste, and raw material, in a cost-effective manner.

“We worked closely with Acasti Pharma to design and engineer a unique and innovative continuous manufacturing process for CaPre [omega-3 phospholipid],” said Yves Michon, CEO of CordenPharma Chenôve. “This process has been installed at CordenPharma Chenôve and will allow us to efficiently scale up the volume of CaPre needed for Acasti’s Phase III trial and early commercial demand.”